Hjem › Crohns sygdom › Iowa
Crohns sygdom kliniske forsøg i Iowa
8 studier for Crohns sygdom søger deltagere på steder i Iowa.
Byer i Iowa
Officiel studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Iowa Digestive Disease Center ( Site 5007), Clive
RekruttererFase 3
Alder 16 til 80 · Alle køn · Opdateret 2. okt. 2026 · NCT06430801A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
- Heartland Medical Research Inc, Clive
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07499232A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
- The University of Iowa Hospitals & Clinics, Iowa City
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 25. sep. 2026 · NCT06233461An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Heartland Medical Research, Inc.-Site Number: 8400134, Clive
- Digestive Health Research Center-Site Number: 8400096, Waterloo
RekruttererFase 3
Alder 16 til 80 · Alle køn · Opdateret 23. sep. 2026 · NCT07184931Zymfentra (Infliximab-dyyb) REal World Cohort STudy
- University of Iowa, Iowa City
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT07237516Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
- University of Iowa Health Care, Iowa City
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 27. apr. 2026 · NCT06456593A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
- Investigational Site Number: 8400025, Iowa City
RekruttererFase 2
Alder 18 til 75 · Alle køn · Opdateret 27. mar. 2026 · NCT06958536Treatment of Moderate to Severe Refractory Crohn's Disease
- University of Iowa, Iowa City
RekruttererFase 1/2
Alder 18 til 65 · Alle køn · Opdateret 10. dec. 2025 · NCT06721962Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.